BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-935@pharmaconomics
DTSTAMP:20260707T050714Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:MIRA Phase 2 — Ketamir-2 (estimated date)
DESCRIPTION:Phase 2 trial results for Ketamir-2 in chemotherapy-induced peripheral neuropathy are due ~ Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1904286/000149315226008707/form8-k.htm\n\nTrack it: https://www.pharmaconomics.com/e/935
URL:https://www.pharmaconomics.com/e/935
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:MIRA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR